LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/Lima Buys Euro ZimmerBiomet Knee and Elbow Systems and Launches Total Knee
Large Joints and Extremities

Lima Buys Euro ZimmerBiomet Knee and Elbow Systems and Launches Total Knee

April 28, 2015 2 min read Premium comments

Advertisement

Lima Buys Euro ZimmerBiomet Knee and Elbow Systems and Launches Total Knee
Courtesy of Lima Corporate
Secondary

Lima Corporate introduced a new total knee in April and agreed to buy the knee and elbow systems from Zimmer Holdings Inc. and Biomet, Inc. that European regulators said needed to be divested in order to approve the Zimmer Biomet merger.

On April 14, 2015, the Udine, Italy-based company announced that it has reached an agreement to buy Zimmer’s Unicompartmental High Flex Knee (ZUK) and Biomet’s Discovery Elbow System within the European Economic Area (EAA) and Switzerland. The company is also taking over Biomet’s Vanguard Complete Knee System through a specific license agreement for Denmark and Sweden.

Lima has been a leading market player with a total shoulder arthroplasty implant that has been on the market for more than 12 years. The European elbow arthroplasty market, according to the company, is estimated to be $17 million.

The company also acquired non-exclusive rights for the manufacturing, marketing and sale of an exact copy of the Vanguard knee in the EEA.

The agreement will become effective after the Zimmer and Biomet deal has been closed. The European Commission approved Lima as a suitable buyer.

Physica Total Knee System

Lima’s new total knee replacement is the Physica System.

The system includes three different types of total knee implants.

Advertisement

“Physica KR is a patented kinematic and posterior cruciate ligament (PCL) retaining design able to induce natural knee kinematics without the use of a constraint mechanism.” The KR “is available for the European market and cleared by the FDA in the U.S.”

“Physica PS is the posterior stabilised solution (PCL sacrificing) with an asymmetric cam which allows an optimized knee kinematic profile and an enhanced load transmission through the tibial post during the entire flexion and extension cycle.”

The system” also includes a CR version or cruciate retaining implant which is PCL retaining and designed to conserve bone to improve load transfer and enable more anatomical patellar tracking. Both the Physica PS and CR are available for the European markets.”

Immediate Market Share

“With the launch of Physica, the acquisition of ZUK puts Lima on the map as a serious player in the knee market, ” said Lima CEO Luigi Ferrari. “To be focused on our historical markets, we decided that the EEA and Switzerland markets would best fit our strategy. The acquisition of the Vanguard portfolio will provide Lima an immediate market share in Denmark and Sweden, countries that are primarily tender-based.”

According to the company, the total knee replacement market in Europe has been estimated to be more than $1 billion in 2013 and is expected to continue to grow. The Unicompartmental (UNI) knee segment represents approximately 6% of the total knee replacement market. Purchasing the Zimmer knee will allow Lima to enter this market.

Lima Corporate

Lima has been known as a company specializing in the production of titanium since the company was founded 70 years ago. The company, according to the press announcement, “has become a reference player with a vertically integrated supply chain and the world’s largest additive manufacturing installment for the orthopedics medical device market. Therefore, Lima will have the capability to autonomously run all production for these three product lines.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy